J.B. Chemicals & Pharmaceuticals cash flow

Latest FY26

Cash from operations: ₹704cr−22.0% on FY25
Capital spending: ₹0.0cr−100.0% on FY25
Free cash flow: ₹704cr−10.0% on FY25
Cash from financing: −₹123cr−₹580 cr in FY25

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	183	171	138	114
	5.6	11.7	44.3	35.4
	−33.8	−5.3	−4.4	−2.5
	0.0	−0.0	0.0	0.0
	−10.7	−5.4	−16.6	−2.9
	71.0	54.9	42.0	69.4
	20.1	5.6	−10.6	−15.8
	18.9	3.0	10.1	1.9
	−154	−26.4	−72.0	−20.5
	−56.6	−49.8	−71.6	−41.8
	−14.5	−26.8	−16.1	−4.0
	0.0	−0.2	0.2	−0.0
	−20.3	83.4	138	32.4
Cash from operating activities
	952	887	752	555
	7.9	216	182	166
	960	1,103	933	721
	256	201	132	95.5
	704	902	801	626
Cash from investing activities
	0.0	97.6	127	72.6
	0.0	22.7	135	692
	0.0	1.1	1.0	0.8
	−1.9	0.0	0.0	0.0
	−83.2	0.0	0.0	0.0
	0.0	0.0	0.0	0.0
	9.8	4.5	4.1	2.2
	−514	−181	−148	−200
	−586	−296	−404	−962
Cash from financing activities
	232	24.0	20.0	8.5
	0.0	0.0	0.0	5.6
	0.0	0.0	0.0	610
	13.8	344	192	87.3
	24.9	13.1	0.0	0.0
	—	—	12.7	9.7
	3.1	9.6	44.2	32.2
	313	237	157	128
	−123	−580	−385	357
	−5.1	26.9	11.3	20.4
	0.2	−0.0	−0.0	0.0
	−4.9	26.9	11.3	20.4
	—	—	88.2	76.9
Reference items
	1,107	1,032	897	696
	26.7%	26.3%	25.7%	22.1%
	704	782	539	−139
	687	429	304	—
	₹43.83	₹48.70	₹33.58	−₹8.68
	0.99×	1.37×	1.45×	1.53×
	256	201	132	95.5
	3.1	9.6	44.2	32.2

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersTORNTPHARM ALKEM IPCALAB SAILIFE NH NEULANDLAB ACUTAAS NATCOPHARM

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	114.4	138.3	171.0	182.5
+ Finance Costs	35.4	44.3	11.7	5.6
+ Interest Income	-2.5	-4.4	-5.3	-33.8
+ Dividend Income	0.0	0.0	-0.0	0.0
+ Fair Value (Gains) / Losses	-2.9	-16.6	-5.4	-10.7
+ Share-based Payments	69.4	42.0	54.9	71.0
+ Unrealised FX (Gain) / Loss	-15.8	-10.6	5.6	20.1
+ Other Non-cash Items	1.9	10.1	3.0	18.9
Changes in Working Capital
+ Inventories	-20.5	-72.0	-26.4	-154.5
+ Trade Receivables — Current	-41.8	-71.6	-49.8	-56.6
+ Other Current Assets	-4.0	-16.1	-26.8	-14.5
+ Other Non-current Assets	-0.0	0.2	-0.2	0.0
+ Trade Payables — Current	32.4	138.0	83.4	-20.3
Cash from Operating Activities
Profit Before Tax (per I/S)	555.2	751.5	887.4	952.3
+ Total Adjustments (incl. Working Capital)	165.9	181.6	215.7	7.9
Cash from Operations (pre-tax)	721.1	933.1	1,103.1	960.2
+ Income Taxes Paid	95.5	132.5	200.7	256.3
Cash from Operating Activities	625.6	800.6	902.5	703.9
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	72.6	126.9	97.6	0.0
+ Acq of Intangible Assets	692.4	134.5	22.7	0.0
+ Disp of Fixed Assets	0.8	1.0	1.1	0.0
+ Acq of Goodwill	0.0	0.0	0.0	-1.9
+ Disp of Biological Assets	0.0	0.0	0.0	-83.2
+ Dividends Received — Investing	0.0	0.0	0.0	0.0
+ Interest Received — Investing	2.2	4.1	4.5	9.8
+ Other Inflows / (Outflows) — Investing	-199.9	-147.5	-181.3	-514.3
Cash from Investing Activities	-961.8	-403.8	-295.9	-585.9
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options	8.5	20.0	24.0	232.0
+ Payments — Change in Ownership of Subsidiaries	5.6	0.0	0.0	0.0
+ Proceeds from Borrowings	610.4	0.0	0.0	0.0
+ Repayment of Borrowings	87.3	191.6	343.9	13.8
+ Payment of Lease Liabilities	0.0	0.0	13.1	24.9
+ Payment of Finance Lease Liabilities	9.7	12.7	—	—
+ Interest Paid	32.2	44.2	9.6	3.1
+ Dividends Paid	127.6	157.0	237.0	313.3
Cash from Financing Activities	356.5	-385.5	-579.7	-123.1
Net Changes in Cash (pre-FX)	20.4	11.3	26.9	-5.1
+ Effect of FX Rate Changes on Cash	0.0	-0.0	-0.0	0.2
Net Changes in Cash	20.4	11.3	26.9	-4.9
Closing Cash	76.9	88.2	—	—
Reference Items
EBITDA	695.8	896.9	1,031.8	1,107.4
EBITDA Margin %	22.09	25.74	26.34	26.70
Free Cash Flow (CFO − Capex)	-139.3	539.3	782.2	703.9
Free Cash Flow to Equity	—	304.0	429.2	687.1
Free Cash Flow per Basic Share	-8.68	33.58	48.70	43.83
Cash Flow to Net Income	1.53	1.45	1.37	0.99
Cash Paid for Taxes	95.5	132.5	200.7	256.3
Cash Paid for Interest	32.2	44.2	9.6	3.1

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.